MindMed to Participate at May Investor Conferences

MindMed, a clinical stage biopharmaceutical company (NASDAQ: MNMD), will participate in investor conferences in May, including the 2024 RBCCM Global Healthcare Conference and HCW's 2nd Annual BioConnect Investor Conference.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

05/09/2024 - 04:01 PM EDT

NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences:

2024 RBCCM Global Healthcare Conference
- Format: Fireside Chat
- Date and Time: Wednesday, May 15, 2024 at 11:00 am EDT
- Location: New York, NY
- Webcast Link: 2024 RBCCM Global Healthcare Conference

HCW's 2nd Annual BioConnect Investor Conference
- Format: 1x1 investor meetings only
- Date: May 20, 2024
- Location: New York, NY

An audio webcast and replay of the fireside chat at the 2024 RBCCM Global Healthcare Conference will be accessible on MindMed’s Investor Relations website for up to 90 days following the event.

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.